Ombretta Turriziani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/670218/publications.pdf

Version: 2024-02-01

99 papers 2,615 citations

279798 23 h-index 214800 47 g-index

100 all docs

 $\begin{array}{c} 100 \\ \\ \text{docs citations} \end{array}$

100 times ranked

4818 citing authors

#	Article	IF	CITATIONS
1	Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. European Radiology, 2020, 30, 6808-6817.	4.5	530
2	A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. Journal of Allergy and Clinical Immunology, 2020, 146, 211-213.e4.	2.9	275
3	Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive naso-pharyngeal swab. Journal of Endocrinological Investigation, 2020, 43, 1819-1822.	3.3	207
4	Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the "Probio-HIV―Clinical Trial. PLoS ONE, 2015, 10, e0137200.	2.5	120
5	Infectious burden and atherosclerosis: A clinical issue. World Journal of Clinical Cases, 2014, 2, 240.	0.8	83
6	Long-Term Exposure to Zidovudine Affects in Vitro and in Vivo the Efficiency of Phosphorylation of Thymidine Kinase. AIDS Research and Human Retroviruses, 1996, 12, 223-228.	1.1	73
7	Correlation of Interferon-Induced Expression of MxA mRNA in Peripheral Blood Mononuclear Cells with the Response of Patients with Chronic Active Hepatitis C to IFN-alpha Therapy. Journal of Interferon and Cytokine Research, 1999, 19, 243-251.	1.2	66
8	Antiviral therapy: old and current issues. International Journal of Antimicrobial Agents, 2012, 40, 95-102.	2.5	62
9	SARSâ€CoVâ€2 presence in seminal fluid: Myth or reality. Andrology, 2021, 9, 23-26.	3. 5	54
10	Prostaglandin A inhibits replication of human immunodeficiency virus during acute infection. Journal of General Virology, 1991, 72, 2797-2800.	2.9	48
11	Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. Journal of Medical Virology, 2008, 80, 766-771.	5.0	38
12	Cytokine storm and histopathological findings in 60 cases of COVID-19-related death: from viral load research to immunohistochemical quantification of major players IL-1 \hat{l}^2 , IL-6, IL-15 and TNF- \hat{l}_\pm . Forensic Science, Medicine, and Pathology, 2022, 18, 4-19.	1.4	37
13	Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115347.	1.8	36
14	Genotypic Resistance of Archived and Circulating Viral Strains in the Blood of Treated HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 518-524.	2.1	35
15	Infectious Agents in Atherosclerotic Cardiovascular Diseases through Oxidative Stress. International Journal of Molecular Sciences, 2017, 18, 2459.	4.1	35
16	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiologica, 2010, 33, 195-206.	0.1	35
17	Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns. BMC Infectious Diseases, 2017, 17, 581.	2.9	34
18	ISG15 expression correlates with HIV-1 viral load and with factors regulating T cell response. Immunobiology, 2016, 221, 282-290.	1.9	32

#	Article	IF	Citations
19	<i>In vitro</i> Selection of Human Immunodeficiency Virus Type 1 Resistant to Ro 31-8959 Proteinase Inhibitor. Antiviral Chemistry and Chemotherapy, 1993, 4, 329-333.	0.6	30
20	Impaired 2′,3′-dideoxy-3′-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. Biochemical Journal, 2002, 368, 325-332.	3.7	29
21	Detection of SARS-COV N2 Gene: Very low amounts of viral RNA or false positive?. Journal of Clinical Virology, 2020, 133, 104660.	3.1	27
22	Anosmia and Ageusia as Predictive Signs of COVID-19 in Healthcare Workers in Italy: A Prospective Case-Control Study. Journal of Clinical Medicine, 2020, 9, 2870.	2.4	27
23	Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19). Virus Research, 2021, 295, 198283.	2.2	26
24	Early collection of saliva specimens from Bell's palsy patients: Quantitative analysis of HHV-6, HSV-1, and VZV. Journal of Medical Virology, 2014, 86, 1752-1758.	5.0	25
25	Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success. Journal of Clinical Virology, 2019, 117, 61-67.	3.1	24
26	Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection. Clinical Microbiology and Infection, 2010, 16, 1518-1524.	6.0	23
27	Molecular diagnosis of SARS-CoV-2 in seminal fluid. Journal of Endocrinological Investigation, 2021, 44, 2675-2684.	3.3	23
28	Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming. Frontiers in Immunology, 2018, 9, 1031.	4.8	22
29	Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients. Medical Microbiology and Immunology, 2014, 203, 207-16.	4.8	20
30	The role of teicoplanin in the treatment of SARSâ€CoVâ€2 infection: A retrospective study in critically ill COVIDâ€19 patients (Teiâ€COVID study). Journal of Medical Virology, 2021, 93, 4319-4325.	5.0	20
31	Cellular factors involved in the induction of resistance of HIV to antiretroviral agents. International Journal of Antimicrobial Agents, 2000, 16, 353-356.	2.5	18
32	Non-Steroidal Anti-Inflammatory Drugs Increase the Antiretroviral Activity of Nucleoside Reverse Transcriptase Inhibitors in HIV Type-1-Infected T-Lymphocytes: Role of Multidrug Resistance Protein 4. Antiviral Therapy, 2009, 14, 1101-1112.	1.0	18
33	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. Sexually Transmitted Infections, 2019, 95, 619-625.	1.9	18
34	May the Drug Transporter P Glycoprotein Affect the Antiviral Activity of Human Immunodeficiency Virus Type 1 Proteinase Inhibitors?. Antimicrobial Agents and Chemotherapy, 2000, 44, 473-474.	3.2	17
35	Decay of HIV Type 1 DNA and Development of Drug-Resistant Mutants in Patients with Primary HIV Type 1 Infection Receiving Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2001, 17, 1599-1604.	1.1	17
36	Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013–2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors. Journal of Global Antimicrobial Resistance, 2017, 10, 106-112.	2.2	17

3

#	Article	IF	CITATIONS
37	Sperm cryopreservation during the SARS-CoV-2 pandemic. Journal of Endocrinological Investigation, 2021, 44, 1091-1096.	3.3	17
38	Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators. Journal of Virology, 2019, 93, .	3.4	16
39	Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virologica, 1994, 38, 297-8.	0.8	15
40	Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. Aids, 2005, 19, 473-479.	2.2	14
41	Study of the Genotypic Resistant Pattern in HIV-Infected Women and Children from Rural West Cameroon. AIDS Research and Human Retroviruses, 2008, 24, 781-785.	1.1	13
42	Interferon-Induced Gene Expression in Cervical Mucosa during Human Papillomavirus Infection. International Journal of Immunopathology and Pharmacology, 2011, 24, 217-223.	2.1	13
43	Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-na \tilde{A} -ve patients: A single-centre experience. Journal of Global Antimicrobial Resistance, 2020, 20, 298-303.	2.2	13
44	CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats. Journal of Virology, 2021, 95, e0135821.	3.4	13
45	Consolidation of molecular testing in clinical virology. Expert Review of Anti-Infective Therapy, 2017, 15, 387-400.	4.4	12
46	Increased expression of IL-32 correlates with IFN- \hat{l}^3 , Th1 and Tc1 in virologically suppressed HIV-1-infected patients. Cytokine, 2019, 120, 273-281.	3.2	12
47	SARSâ€CoVâ€⊋ diagnostics in the virology laboratory of a University Hospital in Rome during the lockdown period. Journal of Medical Virology, 2021, 93, 886-891.	5.0	12
48	Further Study of the Mechanism Underlying the Cellular Resistance to AZT. Biochemical and Biophysical Research Communications, 1996, 228, 797-801.	2.1	11
49	Short Communication: Analysis of the Integrase Gene from HIV Type 1-Positive Patients Living in a Rural Area of West Cameroon. AIDS Research and Human Retroviruses, 2012, 28, 1729-1733.	1.1	11
50	Anti-HIV Antiviral Activity of Stavudine in a Thymidine Kinase-Deficient Cellular Line. Antiviral Therapy, 1998, 3, 191-194.	1.0	11
51	Detection and quantification of EBV, HHV-6 and CMV DNA in the gastrointestinal tract of HIV-positive patients. Infection, 2014, 42, 1033-1037.	4.7	10
52	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains. European Journal of Medicinal Chemistry, 2020, 208, 112696.	5.5	10
53	Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients. Journal of Clinical Virology, 2020, 128, 104450.	3.1	10
54	Drug Combination of AZT and ddl: Synergism of Action and Prevention of Appearance of AZT-Resistance. Antiviral Chemistry and Chemotherapy, 1994, 5, 51-55.	0.6	9

#	Article	IF	CITATIONS
55	Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIVâ€infected patient. Hematological Oncology, 2019, 37, 176-184.	1.7	9
56	Seroprevalence of group B Coxsackieviruses: Retrospective study in an Italian population. Journal of Medical Virology, 2020, 92, 3138-3143.	5.0	9
57	V3 Net Charge: Additional Tool in HIV-1 Tropism Prediction. AIDS Research and Human Retroviruses, 2014, 30, 1203-1212.	1.1	8
58	HIV†coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy. Journal of Medical Virology, 2015, 87, 315-322.	5.0	8
59	High HIV-1 diversity in immigrants resident in Italy (2008–2017). Scientific Reports, 2020, 10, 3226.	3.3	8
60	Host factors and efficacy of antiretroviral treatment. New Microbiologica, 2004, 27, 63-9.	0.1	8
61	Trends in drug resistance-associated mutations in a real-life cohort of Italian patients infected with HIV-1. Journal of Global Antimicrobial Resistance, 2015, 3, 267-272.	2.2	7
62	Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients. AIDS Research and Human Retroviruses, 2016, 32, 654-657.	1.1	7
63	Increased SAMHD1 transcript expression correlates with interferon-related genes in HIV-1-infected patients. Medical Microbiology and Immunology, 2019, 208, 679-691.	4.8	7
64	Comparative analysis of 2 commercial molecular tests for the detection of gastroenteric viruses on stool samples. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114893.	1.8	7
65	Mutational Resistance Pattern of HIV Type 1 in CD14 ⁺ Monocytes, CD4 ⁺ T Cells, and Plasma from Treated Patients. AIDS Research and Human Retroviruses, 2010, 26, 625-634.	1.1	6
66	Analysis of intracellular human immunodeficiency virus (HIV)-1 drug resistance mutations in multi-failed HIV-1-infected patients treated with a salvage regimen: 72-week follow-up. Clinical Microbiology and Infection, 2013, 19, E318-E321.	6.0	6
67	Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis. Clinical Rheumatology, 2022, 41, 2755-2763.	2.2	6
68	P-Glycoprotein Expression by Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients Is Independent from Response to Highly Active Antiretroviral Therapy. Vaccine Journal, 2003, 10, 191-192.	3.1	5
69	Dominant enrichment of phenotypically activated CD38 ⁺ HLA-DR ⁺ CD8 ⁺ T cells, rather than CD38 ⁺ HLA-DR ⁺ CD4 ⁺ T cells, in HIV/HCV coinfected patients on antiretroviral therapy, lournal of Medical Virology, 2016, 88, 1347-1356.	5.0	5
70	Dolutegravir-Based Regimen for Maintenance of Viral Suppression in People Living with HIV: 48-Week Results in Real-Life Setting. AIDS Research and Human Retroviruses, 2021, 37, 478-485.	1.1	5
71	Alteration of thymidine kinase activity in cells treated with an antiviral agent. Journal of Biological Regulators and Homeostatic Agents, 1995, 9, 47-51.	0.7	5
72	Evaluation of performances of VERSANT HCV RNA 1.0 assay (kPCR) and Roche COBAS AmpliPrep/COBAS TaqMan HCV test v2.0 at low level viremia. New Microbiologica, 2016, 39, 224-227.	0.1	5

#	Article	IF	CITATIONS
73	High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19. Clinical Immunology, 2022, 241, 109068.	3.2	5
74	Cellular issues relating to the resistance of HIV to antiretroviral agents. Scandinavian Journal of Infectious Diseases, 2003, 35, 45-48.	1.5	4
75	Dynamics of HIV DNA and Residual Viremia in Patients Treated With a Raltegravir-Containing Regimen. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, e18-e20.	2.1	4
76	Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients. Journal of Clinical Virology, 2016, 76, 20-23.	3.1	4
77	First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing. Journal of Clinical Virology, 2016, 78, 1-3.	3.1	4
78	Comparison of FTD SARS-CoV-2 Assay and RealStar RT-PCR kit 1.0 for the detection of SARS-CoV-2. Journal of Virological Methods, 2021, 298, 114276.	2.1	4
79	External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy. Scientific Reports, 2022, 12, 3291.	3.3	4
80	Analysis of viral nucleic acids in duodenal biopsies from adult patients with celiac disease. European Journal of Gastroenterology and Hepatology, 2022, 34, 1107-1110.	1.6	4
81	The Effects of Prolonged Treatment with Zidovudine, Lamivudine, and Abacavir on a T-Lymphoblastoid Cell Line. AIDS Research and Human Retroviruses, 2006, 22, 960-967.	1.1	3
82	Expression of the mRNA Levels for MDR1, MRP1, MRP4, and MRP5 IN HIV Antiretroviral Naive Patients: Follow-up at 48 Weeks After the Beginning of Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e54-e56.	2.1	3
83	IFN-stimulated gene expression is independent of the IFNL4 genotype in chronic HIV-1 infection. Archives of Virology, 2016, 161, 3263-3268.	2.1	3
84	Copy-Years Viremia and Risk of Virological Failure in Long-Term–Treated HIV Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 423-428.	2.1	3
85	KI and WU Polyomavirus in Respiratory Samples of SARS-CoV-2 Infected Patients. Microorganisms, 2021, 9, 1259.	3.6	3
86	The Synergistic Effect of Time of Exposure, Distance and No Use of Personal Protective Equipment in the Determination of SARS-CoV-2 Infection: Results of a Contact Tracing Follow-Up Study in Healthcare Workers. International Journal of Environmental Research and Public Health, 2021, 18, 9456.	2.6	3
87	Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature New Microbiologica, 2022, 45, 62-72.	0.1	3
88	Lack of Reduction of Thymidine Kinase Activity in Stavudine-Treated HIV-Infected Patients. AIDS Research and Human Retroviruses, 2004, 20, 701-703.	1.1	2
89	SARS-CoV-2 infection: diagnostic testing results occasionally require special attention. Emerging Microbes and Infections, 2020, 9, 1955-1957.	6.5	2
90	Asymptomatic individuals positive for anti-SARS-CoV-2 antibodies negative on molecular swab. Lancet Microbe, The, 2021, 2, e178.	7.3	2

#	Article	IF	CITATIONS
91	Chest computed tomography score, cycle threshold values and secondary infection in predicting COVID-19 mortality. New Microbiologica, 2021, 44, 145-154.	0.1	2
92	Selection of a T-Cell Line Resistant to Stavudine and Zidovudine by Prolonged Treatment with Stavudine. Antiviral Therapy, 2002, 7, 105-111.	1.0	2
93	Dolutegravir-based regimen maintains virological success in a patient with archived mutations to integrase inhibitors. Aids, 2017, 31, 1900-1901.	2.2	1
94	Antiviral Activity of Fecal Water Samples from HIV-1 Infected Subjects Treated with a Specific Probiotic Formulation. Current HIV Research, 2019, 17, 183-189.	0.5	1
95	Anti-HIV antiviral activity of stavudine in a thymidine kinase-deficient cellular line. Antiviral Therapy, 1998, 3, 191-4.	1.0	1
96	Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization. New Microbiologica, 2015, 38, 531-40.	0.1	1
97	Lack of association of Chlamydia pneumoniae with cardiovascular diseases in virologically suppressed HIV patients. New Microbiologica, 2017, 40, 33-37.	0.1	1
98	An epidemiological investigation to reconstruct a probable human immunodeficiency virus -1 transmission network: a case report. Journal of Medical Case Reports, 2015, 9, 253.	0.8	0
99	(Auto)Antibody Responses Shape Memory NK Cell Pool Size and Composition. Biomedicines, 2022, 10, 625.	3.2	O